Patrice Jean has over a decade of experience counseling leading and start-up pharmaceutical, chemical, and biotechnology companies in all areas of patent law. In particular, she is adept at asserting and defending the patent rights underlying the core technologies and innovations of leading hi-tech and pharmaceutical companies. She also defends her clients against damages claims asserted by competitors, sparing them billions of dollars in damages. Additionally, her patent prosecution practice strengthens her litigation abilities, allowing her to argue the validity of her clients’ patents while challenging the validity of third-party patents.
Dr. Jean regularly calls on her technical background in biology to offer her clients an in-depth understanding of the complex science relative to each prosecution and litigation matter that she handles. This vantage point leaves her well-positioned to understand the complex science behind her clients’ innovations as well as the broader market implications.
Prior to law school, Dr. Jean earned her Ph.D. in molecular biology. She conducted research in various areas of biology and biochemistry including virology, oncology, kidney disease, X-ray crystallography, and narcotics addiction. Her doctoral thesis is entitled “Tissue, Strain, Gender and Age Variation in the Induction of p53 Activated Transcripts in Response to Cellular Stress.”
Dr. Jean is committed to advancing the progress of diversity in the legal profession. She is a 2014 Fellow of the Leadership Council on Legal Diversity, an organization of corporate chief legal officers and managing partners devoted to improving diversity in the legal profession. She is also co-chair of the firm’s Diversity Committee and an Executive Committee Member for the Hon. William C. Conner IP Inn of Court.
- Teva in consolidated Hatch-Waxman litigations concerning proposed generic equivalents to Teva's blockbuster multiple sclerosis drug COPAXONE®. Teva Pharmaceuticals USA v. Sandoz and Teva Pharmaceuticals USA v. Mylan Pharmaceuticals et al. (S.D.N.Y.)
- Intervet in patent infringement litigation concerning patents related to porcine circovirus vaccine technology. Achieved favorable claim construction rulings. Wyeth v. Intervet (D. Del.)
- Intervet in patent litigation resulting in favorable ruling including summary judgment of non-infringement. Intervet v. Merial Limited et al. (D.D.C.)
- Teva Pharmaceuticals against multi-billion dollar damages claim in case relating to Pfizer’s epilepsy drug Neurontin® (gabapentin). Achieved favorable ruling including summary judgment rulings. Pfizer v. Teva Pharmaceuticals USA et al. (D.N.J.)
- Institut Pasteur and the Centre National de la Recherche Scientifique in patent litigation resulting in a favorable summary judgment ruling regarding ownership of a portfolio of 13 patents related to DNA “molecular combing” technology. The ruling confirmed that the world-renowned French research institutions are the rightful owners of the entire portfolio of patents. Institut Pasteur v. Simon (E.D. Pa.)
- “Protecting Life Science Inventions in View of the USPTO’s ‘Guidance for Determining Subject Matter Eligibility of Claims Reciting or Involving Law of Nature, Natural Phenomena, and Natural Products,’” Bloomberg BNA Life Sciences Law & Industry Report, April 4, 2014.
- “A Year of Changes for Life Sciences IP,” Law360, December 18, 2013.
- “Myriad: Practice Points and Considerations,” Intellectual Property Today, September 24, 2013.
- “Patent Law: Biotechnology Update,” American Bar Association, July 15, 2013.
- “Protecting Self-Replicating Biotechnologies in View of Bowman v. Monsanto,” Bloomberg BNA’s Patent, Trademark & Copyright Journal, June 14, 2013.
- “Myriad Ruling: Some Clarity, Some Uncertainty for Biotech,” Law360, June 14, 2013.